Ocumension Therapeutics (HKG:1477)
7.33
+0.37 (5.32%)
At close: Mar 27, 2026
Ocumension Therapeutics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 402.46 | 769.21 | 1,054 | 1,314 | 1,785 |
Cash & Short-Term Investments | 402.46 | 769.21 | 1,054 | 1,314 | 1,785 |
Cash Growth | -47.68% | -27.01% | -19.83% | -26.37% | -12.99% |
Accounts Receivable | 339.62 | 164.07 | 119.36 | 112.71 | 18.51 |
Other Receivables | - | - | - | - | 25.84 |
Receivables | 339.62 | 164.07 | 119.36 | 112.71 | 44.35 |
Inventory | 63.92 | 45.52 | 32.47 | 24.1 | 4.99 |
Other Current Assets | 145.04 | - | - | 3.9 | - |
Total Current Assets | 951.04 | 978.8 | 1,206 | 1,455 | 1,835 |
Property, Plant & Equipment | 456.61 | 451.53 | 467.65 | 448.07 | 365.86 |
Long-Term Investments | 9.07 | 12.93 | 364.15 | 95 | 272.4 |
Other Intangible Assets | 2,601 | 2,438 | 1,140 | 919.05 | 709.97 |
Other Long-Term Assets | 73.43 | 92.43 | 93.39 | 126.4 | 148.25 |
Total Assets | 4,091 | 3,974 | 3,271 | 3,044 | 3,331 |
Accounts Payable | 191.59 | 34.42 | 25.19 | 21.7 | 4.41 |
Accrued Expenses | - | 82.27 | 100.35 | 140.94 | 89.04 |
Short-Term Debt | - | - | 120 | - | - |
Current Portion of Long-Term Debt | 52.17 | 2.06 | - | - | - |
Current Portion of Leases | 10.22 | 6.84 | 12.33 | 12.29 | 4.19 |
Current Income Taxes Payable | 0.03 | 1.04 | 0.34 | 1.55 | 2.4 |
Current Unearned Revenue | 2.75 | 7.59 | 9.05 | - | - |
Other Current Liabilities | - | 20.79 | 48.02 | 71.18 | 115.82 |
Total Current Liabilities | 256.76 | 155 | 315.28 | 247.65 | 215.85 |
Long-Term Debt | 106.04 | 14.49 | - | - | - |
Long-Term Leases | 19.11 | 2.39 | 5.66 | 17.29 | 7.03 |
Long-Term Unearned Revenue | 28.3 | 28.3 | 30.09 | 30.09 | - |
Total Liabilities | 410.21 | 200.19 | 351.03 | 295.04 | 222.88 |
Common Stock | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 |
Additional Paid-In Capital | - | 8,844 | 7,626 | 7,511 | 7,355 |
Retained Earnings | - | -4,876 | -4,722 | -4,447 | -4,045 |
Treasury Stock | - | -0 | -0 | -0 | -0 |
Comprehensive Income & Other | 3,681 | -194.51 | 15.95 | -315.8 | -202.79 |
Total Common Equity | 3,681 | 3,774 | 2,920 | 2,749 | 3,108 |
Shareholders' Equity | 3,681 | 3,774 | 2,920 | 2,749 | 3,108 |
Total Liabilities & Equity | 4,091 | 3,974 | 3,271 | 3,044 | 3,331 |
Total Debt | 187.54 | 25.78 | 137.98 | 29.58 | 11.21 |
Net Cash (Debt) | 214.93 | 743.42 | 915.82 | 1,285 | 1,774 |
Net Cash Growth | -71.09% | -18.82% | -28.72% | -27.57% | -13.23% |
Net Cash Per Share | 0.27 | 1.09 | 1.41 | 2.03 | 2.92 |
Filing Date Shares Outstanding | 798.91 | 815.73 | 690.66 | 688.74 | 618.42 |
Total Common Shares Outstanding | 798.91 | 815.73 | 690.66 | 688.74 | 618.42 |
Working Capital | 694.28 | 823.79 | 890.35 | 1,208 | 1,619 |
Book Value Per Share | 4.61 | 4.63 | 4.23 | 3.99 | 5.03 |
Tangible Book Value | 1,080 | 1,335 | 1,780 | 1,830 | 2,398 |
Tangible Book Value Per Share | 1.35 | 1.64 | 2.58 | 2.66 | 3.88 |
Machinery | - | 394.82 | 383.13 | 93.79 | 10.1 |
Construction In Progress | - | 93.56 | 86.22 | 323.86 | 336.98 |
Leasehold Improvements | - | 15.21 | 13.49 | 9.55 | 3.61 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.